VANDA PHARMACEUTICALS INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
VANDA PHARMACEUTICALS INC. (VNDA) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 44.74 million shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2018-02-15
- VANDA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2017-12-31 was 44.93M shares, a 2.18% increase year-over-year.
- VANDA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2017-09-30 was 44.89M shares, a 3.15% increase year-over-year.
- VANDA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2017-06-30 was 44.72M shares, a 3.51% increase year-over-year.
- VANDA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2017-03-31 was 44.40M shares, a 3.00% increase year-over-year.
- VANDA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 44.74M shares, a 2.96% increase from fiscal 2016.
- VANDA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for fiscal 2016 was 43.45M shares, a 2.84% increase from fiscal 2015.
- VANDA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic and diluted for fiscal 2015 was 42.25M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2017-12-31 | 44.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | 44.91M shares derived: average of 2 quarters · filed 2018-02-15 | 44.85M shares derived: average of 3 quarters · filed 2018-02-15 | 44.74M shares 10-K · filed 2018-02-15 |
| 2017-09-30 | 44.89M shares 10-Q · filed 2017-11-08 | 44.80M shares derived: average of 2 quarters · filed 2017-11-08 | 44.67M shares 10-Q · filed 2017-11-08 | 44.49M shares derived: average of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | 44.72M shares 10-Q · filed 2017-08-03 | 44.56M shares 10-Q · filed 2017-08-03 | 44.36M shares derived: average of 3 quarters · filed 2018-02-15 | 44.15M shares derived: average of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | 44.40M shares 10-Q · filed 2017-05-03 | 44.19M shares derived: average of 2 quarters · filed 2018-02-15 | 43.96M shares derived: average of 3 quarters · filed 2018-02-15 | 43.77M shares derived: average of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | 43.97M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | 43.74M shares derived: average of 2 quarters · filed 2018-02-15 | 43.56M shares derived: average of 3 quarters · filed 2018-02-15 | 43.45M shares 10-K · filed 2018-02-15 |
| 2016-09-30 | 43.52M shares 10-Q · filed 2017-11-08 | 43.36M shares derived: average of 2 quarters · filed 2017-11-08 | 43.28M shares 10-Q · filed 2017-11-08 | 43.16M shares derived: average of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | 43.20M shares 10-Q · filed 2017-08-03 | 43.15M shares 10-Q · filed 2017-08-03 | 43.04M shares derived: average of 3 quarters · filed 2018-02-15 | 42.89M shares derived: average of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | 43.10M shares 10-Q · filed 2017-05-03 | 42.96M shares derived: average of 2 quarters · filed 2018-02-15 | 42.79M shares derived: average of 3 quarters · filed 2018-02-15 | 42.59M shares derived: average of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | 42.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | 42.63M shares derived: average of 2 quarters · filed 2018-02-15 | 42.42M shares derived: average of 3 quarters · filed 2018-02-15 | 42.25M shares 10-K · filed 2018-02-15 |
| 2015-09-30 | 42.44M shares 10-Q · filed 2016-11-03 | 42.21M shares derived: average of 2 quarters · filed 2016-11-03 | 42.06M shares 10-Q · filed 2016-11-03 | |
| 2015-06-30 | 41.99M shares 10-Q · filed 2016-07-28 | 41.87M shares 10-Q · filed 2016-07-28 | ||
| 2015-03-31 | 41.74M shares 10-Q · filed 2016-05-05 | |||
| 2014-09-30 | 33.89M shares 10-Q · filed 2015-11-04 | 33.88M shares derived: average of 2 quarters · filed 2015-11-04 | 33.81M shares 10-Q · filed 2015-11-04 | |
| 2014-06-30 | 33.87M shares 10-Q · filed 2015-07-31 | 33.78M shares 10-Q · filed 2015-07-31 | ||
| 2014-03-31 | 33.68M shares 10-Q · filed 2015-05-07 | |||
| 2013-09-30 | 31.33M shares 10-Q · filed 2014-10-27 | 29.86M shares derived: average of 2 quarters · filed 2014-10-27 | 29.36M shares 10-Q · filed 2014-10-27 | |
| 2013-06-30 | 28.38M shares 10-Q · filed 2014-08-08 | 28.36M shares 10-Q · filed 2014-08-08 | ||
| 2013-03-31 | 28.35M shares 10-Q · filed 2014-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |